Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.